Telix Pharmaceuticals was created to deliver on the promise of nuclear medicine
The field of nuclear medicine has historically lacked clinical momentum and commitment to late-stage product development. Our goal is to rectify this for the benefit of patients.
Telix Pharmaceuticals Enters Strategic Collaboration with Varian Medical Systems for Advanced Prostate Imaging
Melbourne (Australia) and Palo Alto, CA (USA) – 3rd September 2020. Telix announces it has entered into a strategic collaboration...
Telix Pharmaceuticals and IRE Elit Enter Distribution Partnership for Prostate Cancer Imaging
Herstal and Fleurus (Belgium) – 1st September 2020. Telix announces distribution agreement with Fleurus-based IRE Elit S.A. to distribute Telix’s...
FDA Grants Orphan Drug Designation for TLX102
Melbourne (Australia) – 31st August 2020. Telix announces the FDA has granted ODD for 4-[211At] astato-l-phenylalanine for the treatment of...
Half Year Shareholder Update
Melbourne (Australia) – 21st August 2020. Telix Pharmaceuticals Limited Announces Half-year Shareholder Update